Free Trial

Athira Pharma (LONA) 10K Form and Latest SEC Filings 2026

Athira Pharma logo
$9.63 +0.08 (+0.84%)
Closing price 03:59 PM Eastern
Extended Trading
$9.60 -0.04 (-0.36%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Athira Pharma SEC Filings & Recent Activity

Athira Pharma (NASDAQ:LONA) has submitted 286+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on April 13, 2026.

Form 4
LeonaBio, Inc. Reports Ownership Change on Apr. 13, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Athira Pharma Files Current Report on Mar. 31, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Athira Pharma Files Annual Report on Mar. 31, 2026

The 10-K contains Athira Pharma's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Athira Pharma SEC Filing History

Browse Athira Pharma's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/13/2026 3:51 PM
Athira Pharma (1620463) Issuer
San Martin Javier (1794629) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:52 PM
EDELMAN JOSEPH (1164426) Reporting
Athira Pharma (1620463) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:53 PM
JOHNSON JAMES A (1225501) Reporting
Athira Pharma (1620463) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:54 PM
Athira Pharma (1620463) Issuer
Romano Kelly A (1722055) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:55 PM
Athira Pharma (1620463) Issuer
PICKERING GRANT (1258693) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:56 PM
Kosacz Barbara (1763316) Reporting
Athira Pharma (1620463) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:58 PM
CHURCH KEVIN (1822499) Reporting
Athira Pharma (1620463) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:59 PM
Athira Pharma (1620463) Issuer
Panzara Michael A. (1679039) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:46 PM
Athira Pharma (1620463) Issuer
Litton Mark James (1604834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:47 PM
Athira Pharma (1620463) Issuer
Renninger Robert (2037968) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:48 PM
Athira Pharma (1620463) Issuer
Worthington Mark (1861464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:49 PM
FLUKE JOHN M JR (1191906) Reporting
Athira Pharma (1620463) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 8:30 PM
Athira Pharma (1620463) Filer
Form 424B3
04/01/2026 8:30 PM
Athira Pharma (1620463) Filer
Form 424B3
04/01/2026 11:15 PM
Athira Pharma (1620463) Filer
Form EFFECT
04/01/2026 11:15 PM
Athira Pharma (1620463) Filer
Form EFFECT
04/01/2026 3:05 PM
Athira Pharma (1620463) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
04/01/2026 3:07 PM
Athira Pharma (1620463) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/31/2026 3:59 PM
Athira Pharma (1620463) Filer
Form S-1/A
03/31/2026 4:07 PM
Athira Pharma (1620463) Filer
Form S-1/A
03/31/2026 3:11 PM
Athira Pharma (1620463) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/31/2026 1:20 PM
Athira Pharma (1620463) Filer
Form 8-K/A
03/19/2026 3:50 PM
Athira Pharma (1620463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2026 3:20 PM
Athira Pharma (1620463) Filer
Form DEFR14A
03/05/2026 6:14 PM
Athira Pharma (1620463) Issuer
Litton Mark James (1604834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:59 PM
Athira Pharma (1620463) Issuer
San Martin Javier (1794629) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 6:02 PM
CHURCH KEVIN (1822499) Reporting
Athira Pharma (1620463) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 6:06 PM
Athira Pharma (1620463) Issuer
Worthington Mark (1861464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 6:10 PM
Athira Pharma (1620463) Issuer
Renninger Robert (2037968) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 6:47 PM
Athira Pharma (1620463) Subject
Litton Mark James (1604834) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/06/2026 3:29 PM
Baselake Partners, LP (1957912) Filed by
Athira Pharma (1620463) Subject
Form SCHEDULE 13G/A
02/04/2026 3:53 PM
Athira Pharma (1620463) Filer
Form PRE 14A
01/20/2026 3:42 PM
Athira Pharma (1620463) Filer
Form S-3
Registration statement under Securities Act of 1933  
01/16/2026 3:46 PM
Athira Pharma (1620463) Subject
PERCEPTIVE ADVISORS LLC (1224962) Filed by
Form SCHEDULE 13D/A
01/09/2026 3:05 PM
Athira Pharma (1620463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 4:29 PM
ACORN BIOVENTURES, L.P. (1766853) Filed by
Athira Pharma (1620463) Subject
Form SCHEDULE 13G/A
01/05/2026 6:49 PM
Athira Pharma (1620463) Issuer
Worthington Mark (1861464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 6:50 PM
Athira Pharma (1620463) Issuer
CHURCH KEVIN (1822499) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 6:50 PM
Athira Pharma (1620463) Issuer
Renninger Robert (2037968) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 6:51 PM
Athira Pharma (1620463) Issuer
Litton Mark James (1604834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 6:52 PM
Athira Pharma (1620463) Issuer
San Martin Javier (1794629) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:12 PM
Athira Pharma (1620463) Issuer
Worthington Mark (1861464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:14 PM
Athira Pharma (1620463) Issuer
San Martin Javier (1794629) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:15 PM
Athira Pharma (1620463) Issuer
CHURCH KEVIN (1822499) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:17 PM
Athira Pharma (1620463) Issuer
Litton Mark James (1604834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:19 PM
Athira Pharma (1620463) Issuer
Renninger Robert (2037968) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 4:16 PM
Athira Pharma (1620463) Subject
PERCEPTIVE ADVISORS LLC (1224962) Filed by
Form SCHEDULE 13D/A
12/23/2025 4:12 PM
Athira Pharma (1620463) Issuer
EDELMAN JOSEPH (1164426) Reporting
PERCEPTIVE ADVISORS LLC (1224962) Reporting
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (1249675) Reporting
Perceptive Xontogeny Venture Fund II, LP (1851820) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:46 PM
ACORN BIOVENTURES, L.P. (1766853) Filed by
Athira Pharma (1620463) Subject
Form SCHEDULE 13G
12/22/2025 3:30 PM
Athira Pharma (1620463) Subject
PERCEPTIVE ADVISORS LLC (1224962) Filed by
Form SCHEDULE 13D/A
12/18/2025 2:47 PM
Athira Pharma (1620463) Subject
BML Investment Partners, L.P. (1373604) Filed by
Form SCHEDULE 13G/A
12/18/2025 7:24 AM
Athira Pharma (1620463) Filer
Form 8-K/A
12/18/2025 6:16 AM
Athira Pharma (1620463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 3:06 PM
Athira Pharma (1620463) Subject
Baselake Partners, LP (1957912) Filed by
Form SCHEDULE 13G
11/06/2025 3:09 PM
Athira Pharma (1620463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2025 3:13 PM
Athira Pharma (1620463) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/10/2025 3:41 PM
Athira Pharma (1620463) Subject
Oliveira Steven Michael (1358629) Filed by
Form SCHEDULE 13G/A
10/03/2025 8:11 AM
Athira Pharma (1620463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2025 8:00 AM
Athira Pharma (1620463) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/02/2025 3:32 PM
Athira Pharma (1620463) Issuer
Renninger Robert (2037968) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025 3:33 PM
Athira Pharma (1620463) Issuer
Worthington Mark (1861464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025 3:33 PM
Athira Pharma (1620463) Issuer
San Martin Javier (1794629) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025 6:33 PM
Athira Pharma (1620463) Subject
Worthington Mark (1861464) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/01/2025 6:34 PM
Athira Pharma (1620463) Subject
CHURCH KEVIN (1822499) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/01/2025 6:36 PM
Athira Pharma (1620463) Subject
San Martin Javier (1794629) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/01/2025 6:37 PM
Athira Pharma (1620463) Subject
Litton Mark James (1604834) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2025 4:32 PM
Athira Pharma (1620463) Issuer
PICKERING GRANT (1258693) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 4:33 PM
Athira Pharma (1620463) Issuer
Kosacz Barbara (1763316) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 4:34 PM
Athira Pharma (1620463) Issuer
JOHNSON JAMES A (1225501) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 4:34 PM
Athira Pharma (1620463) Issuer
EDELMAN JOSEPH (1164426) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 4:35 PM
Athira Pharma (1620463) Issuer
Romano Kelly A (1722055) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 4:36 PM
Athira Pharma (1620463) Issuer
Panzara Michael A. (1679039) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025 4:37 PM
Athira Pharma (1620463) Issuer
FLUKE JOHN M JR (1191906) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2025 3:15 PM
Athira Pharma (1620463) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Athira Pharma SEC Filings - Frequently Asked Questions

Athira Pharma (LONA) has submitted 286+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Athira Pharma's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 4 submitted on April 13, 2026. This was an insider ownership change filed by 4 - LeonaBio, Inc. (0001620463) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:LONA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners